Invader Assay definition

Invader Assay means a method and compositions for detecting and/or quantifying a specific nucleic acid target sequence within a nucleic acid mixture that is dependent upon the coordinate actions of two (2) target-specific probes and a structure-specific nuclease, and that uses TWT Technology.
Sample 1Sample 2
Invader Assay means a biochemical test comprising *** of a *** that is *** that ***.
Sample 1
Invader Assay means a biochemical test comprising the detection or quantification of a nucleic acid that is dependent upon the coordinate action of at least an Invader Probe, a Primary Probe, and a Cleavage Enzyme that cleaves an Overlap Region formed when an Invader Probe and a Primary Probe hybridize to the nucleic acid.
Sample 1

Examples of Invader Assay in a sentence

  • STANFORD hereby agrees that it will not develop, make or use any Invader Assay, and will not use any Standard Invader Reagent Plate, Software or other materials supplied by TWT, for any Agricultural Application without the prior written consent of TWT or except as expressly permitted herein.

  • Without limiting the foregoing and unless otherwise agreed in writing by TWT, STANFORD shall not use any Invader Assay in any application that would conflict with the rights granted to TWT herein or on behalf of any third party (e.g., on a service basis) or allow any third party access to any Invader Assay.

  • TWT will have the non-exclusive right to use such data for SNP Invader Assay quality control and trouble shooting and for software analysis and internal technology development.

  • It is understood that for each SNP Invader Assay supplied pursuant to this MOU, TWT will provide GRL at least 350 typing determinations and the quality control data for such SNP Invader Assay.

  • Subject to both satisfactory completion of the Study and GRL securing specific funding, it is the intention of the parties that the parties will extend the Study to approximately an additional 1,750 samples at the same price per determination as set forth herein [****] Standard Invader Reagents per typing determination, and no charge for an additional 5.25ml of SNP-specific Probe Sets (1(mu)M Signal probe/2(mu)M Invader probe) for each SNP Invader Assay).

  • Subject to the terms and conditions set forth in this MOU, promptly after acceptance of this MOU by GRL, TWT will use diligent efforts to develop and supply Invader(TM) Assays for up to 2,000 single nucleotide polymorphisms (SNPs) designated by GRL as set forth on Exhibit A (each, a "SNP Invader Assay") in accordance with the schedule set forth on Exhibit A.

Related to Invader Assay

  • Companion Diagnostic means a device which is essential for the safe and effective use of a corresponding medicinal product to:

  • Third Party Components means software and interfaces, licensed by RIM from a third party for incorporation into a RIM software product, or for incorporation into firmware in the case of RIM hardware products, and distributed as an integral part of that RIM product under a RIM brand, but shall not include Third Party Software.

  • Third Party Manufacturer means (i) a Third Party whose primary business is contract manufacturing, or (ii) a Third Party who has a contractual arrangement with Licensee or with a sublicensee of Licensee that includes manufacturing of Client Product and/or Drug Product by such Third Party for Licensee or such sublicensee.

  • Phase I Clinical Study means, as to a particular Licensed Product, an initial clinical study in humans with the purpose of assessing the Licensed Product’s safety, tolerability, toxicity, pharmacokinetics or other pharmacological properties.

  • Phase II Clinical Study means a human clinical study of a product initiated to determine the safety and efficacy in the target patient population, as described 21 C.F.R. 312.21(b).

  • Development Candidate means a Compound that meets the Development Candidate Criteria for the initiation of a Development Program for the treatment of CF, and which is the subject of a notice from Vertex to CFFT that Vertex intends to commence formal pre-clinical development of the Compound in the Field pursuant to the provisions of Section 3.1 hereof.

  • Clinical Study or “Clinical Studies” means a Phase 0 Xxxxx, Xxxxx 0 Xxxxx, Xxxxx 0 Trial or Phase 4 Trial, or such other study in humans that is conducted in accordance with good clinical practices and is designed to generate data in support or maintenance of an NDA, MAA or other similar marketing application.

  • Biomarker means a parameter or characteristic in a patient or Patient Sample, the measurement of which is useful (a) for purposes of selecting appropriate therapies or patient populations or monitoring disease susceptibility, severity or state, or monitoring therapies for such patient and/or (b) for predicting the outcome of a particular treatment of such patient.

  • Gene Therapy means a product or service for the treatment or prevention of a disease that utilizes ex vivo or in vivo delivery (via viral or nonviral gene transfer methods or systems) of Genetic Material, including any cell incorporating Genetic Material.

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Commercialization or “Commercialize” means any and all activities undertaken at any time for a particular Licensed Product and that relate to the manufacturing, marketing, promoting, distributing, importing or exporting for sale, offering for sale, and selling of the Licensed Product, and interacting with Regulatory Authorities regarding the foregoing.